Divestments hurt Moberg
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Offloading a number of ‘non-core’ brands left turnover at Moberg Pharma down by 12% to SEK91.5 million (€8.9 million) in the first-quarter of 2018.
You may also be interested in...
Moberg Sells Consumer Health Portfolio To Pay For Rx Research Focus
Moberg had been expanding its OTC portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands.
Moberg Sells Consumer Health Portfolio To Pay For Focusing On Rx Research
Moberg had been expanding its OTC topical and nutritional supplement portfolio while also continuing trials for Rx ingredients including its MOB-015 formulation of terbinafine indicated for fingernail and toenail fungus. But $155m agreement with two investment groups will complete Moberg's divestment of consumer health brands and make it dedicated to R&D, regulatory matters and business development.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.